국소 지혈제 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Topical Hemostat Market Size, Share & Trends Analysis Report By Type (Thrombin, Collagen, Gelatin), By Application (General Surgery, Cardiovascular Surgery), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

국소 지혈제 시장 규모와 동향:

국소 지혈제 세계 시장 규모는 2024년 59억 달러로 2025년부터 2030년까지 연평균 9.4%로 성장할 것으로 예상됩니다. 이 산업은 외과 수술의 증가, 외상 사례의 증가, 지혈 기술의 발전으로 인해 성장하고 있습니다. 이 제품들은 심혈관, 정형외과, 신경외과 등의 수술에서 출혈을 조절하기 위해 널리 사용되고 있습니다. 상처 치유 가속화, 수술 합병증 감소, 환자 결과 개선에 대한 요구가 수요를 견인하고 있습니다. 특히 신흥 시장의 의료 인프라 성장과 최소침습 수술의 증가는 시장 성장을 더욱 촉진할 것입니다.

최근 한 사례는 거즈와 같은 기존 지혈제의 한계가 드러난 바 있습니다. 수술 후 환자에게 의도치 않게 지혈재가 존재하여 통증, 염증, 감염을 유발한 것입니다. 거즈나 의료용 밴드와 같은 기존 재료는 주로 표면 출혈을 억제하지만, 출혈 부위에 대한 접착력이 부족하고 오염되기 쉽습니다. 피브린 접착제나 콜라겐 스펀지와 같은 대체 재료는 생분해성이 있지만, 인간 또는 동물 유래 단백질에 의존하기 때문에 비용이 많이 듭니다.

연구진은 이러한 한계를 극복하기 위해 홍합과 누에고치에서 추출한 천연 단백질을 이용한 혁신적인 이중층 나노섬유막 지혈제를 개발했습니다. 이 새로운 지혈재는 강력한 조직 접착력, 효과적인 출혈 제어 및 감염 방어를 제공합니다. 차현준 교수를 중심으로 한 POSTECH, 이화여대, 서울성모병원 공동 연구팀은 이 조사를 2024년 2월 학술지 Small에 발표했습니다. 이 지혈제는 신속한 지혈을 위해 혈소판을 활성화하는 조개 접착 단백질과 메탄올 증기로 개질된 소수성 나노섬유 외층을 형성하는 누에의 실크 피브로인을 통합한 것입니다. 이 이중층 구조는 생체적합성, 생분해성, 강력한 감염 예방을 보장합니다.

동물 실험에서 이 약물이 출혈 상처의 조직 접착과 지혈을 촉진하는 능력이 있음이 입증되었습니다. 내층은 접착을 촉진하고 외층은 수계 오염 물질과 박테리아로부터 보호합니다. 이러한 발전은 기존 지혈 재료의 심각한 단점을 해결하고 외과적 용도에 보다 안전하고 다기능적인 솔루션을 제공합니다. 연구팀은 이 지혈제가 실제 수술에 사용될 수 있으며 환자 치료에 큰 영향을 미칠 수 있다고 강조했습니다.

산업계는 이러한 기술 혁신에 대한 인식의 증가와 자금 지원 및 연구 지원의 혜택을 누리고 있습니다. 한국해양바이오소재연구센터 프로그램과 한국연구재단의 지원을 받은 이번 조사는 시장 성장을 촉진하기 위한 정부 이니셔티브의 중요성을 강조하고 있습니다. 첨단적이고 비용 효율적이며 생체적합성이 높은 지혈제에 대한 수요가 증가함에 따라 기술적 혁신과 안전한 수술 결과를 위한 지속적인 노력에 힘입어 지혈제 시장은 크게 확대될 것으로 예상됩니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 국소 지혈제 시장 : 변수, 동향, 범위

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 국소 지혈제 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 국소 지혈제 시장 : 종류별 추정·동향 분석

• 부문 대시보드
• 국소 지혈제 시장 : 변동 분석, 종류별
• 국소 지혈제 시장 전망 : 종류별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 피브린
• 트롬빈
• 셀룰로오스
• 콜라겐
• 젤라틴
• 접착제
• 기타

제5장 국소 지혈제 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 국소 지혈제 시장 : 변동 분석, 용도별
• 국소 지혈제 시장 전망 : 용도별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 일반외과
• 신경외과
• 혈관외과
• 심혈관외과
• 기타

제6장 국소 지혈제 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 국소 지혈제 시장 : 변동 분석, 최종 용도별
• 국소 지혈제 시장 전망 : 최종 용도별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 병원
• 외래 수술 센터
• 기타

제7장 국소 지혈제 시장 : 지역별 추정·동향 분석

• 지역 대시보드
• 국소 지혈제 시장 : 변동 분석, 기술별
• 국소 지혈제 시장 전망 : 기술별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 시장 진출 기업 분류
• 주요 기업 개요
  • BD
  • Medicom
  • Baxter
  • HemoSonics
  • Hemostasis, LLC
  • Medline Industries
  • Pfizer Inc.
  • Johnson & Johnson
  • HemCon Medical Technologies Inc.
  • Integra LifeSciences
  • Teleflex Incorporated

ksm

영문 목차

영문목차

Topical Hemostat Market Size & Trends:

The global topical hemostat market size was valued at USD 5.9 billion in 2024 and is projected to grow at a CAGR of 9.4% from 2025 to 2030. The industry is growing due to rising surgical procedures, increasing trauma cases, and advancements in hemostatic technologies. These products are widely used to control bleeding in surgeries, including cardiovascular, orthopedic, and neurosurgical procedures. The demand is fueled by the need for faster wound healing, reduced surgical complications, and improved patient outcomes. Growing healthcare infrastructure, particularly in emerging markets, and the rise in minimally invasive procedures further drive market growth.

A recent case underscored the limitations of conventional hemostatic materials like gauze, where its unintended presence in a patient post-surgery caused pain, inflammation, and infection. Traditional materials such as gauze and medical bands primarily control surface bleeding but lack adherence to bleeding sites and are prone to contamination. Alternatives like fibrin glue and collagen sponges, though biodegradable, are expensive due to reliance on human or animal-derived proteins.

Researchers have addressed these limitations and developed an innovative bilayer nanofiber membrane hemostat using natural proteins from mussels and silkworm cocoons. This novel hemostat offers strong tissue adhesion, effective bleeding control, and protection against infection. Led by Professor Hyung Joon Cha and a collaborative team from POSTECH, Ewha Womans University, and Seoul St. Mary's Hospital, the research was published in the journal Small in February 2024. The hemostatic agent integrates mussel adhesive proteins, which activate platelets for rapid hemostasis, and silk fibroin from silkworms, modified with methanol vapor to create a hydrophobic nanofiber outer layer. This dual-layer design ensures biocompatibility, biodegradability, and robust infection prevention.

Animal experiments demonstrated the agent's ability to accelerate tissue adhesion and hemostasis in bleeding wounds. Its inner layer enhances adhesion while the outer layer protects against waterborne contaminants and bacteria. These advancements address critical shortcomings in existing hemostatic materials, offering a safer, multifunctional solution for surgical applications. The research team emphasized the agent's potential for real-world surgical settings and its transformative impact on patient care.

The industry benefits from growing awareness of such innovations, as well as funding and research support. This study, supported by Korea's Marine Bio Materials Research Center Program and the National Research Foundation, highlights the importance of government initiatives in driving market growth. As demand for advanced, cost-effective, and biocompatible hemostatic agents rises, the market is poised for substantial expansion, propelled by technological breakthroughs and the continuous pursuit of safer surgical outcomes.

Global Topical Hemostat Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global topical hemostat market report on the basis of type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Fibrin
• Thrombin
• Cellulose
• Collagen
• Gelatin
• Adhesives
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• General Surgery
• Neurosurgery
• Vascular Surgery
• Cardiovascular Surgery
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Ambulatory Surgical Centers
• Others
• Region Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End-use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Topical Hemostat Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Topical Hemostat Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Topical Hemostat Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Topical Hemostat Market: Type Movement Analysis
• 4.3. Topical Hemostat Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Fibrin
  • 4.5.1. Fibrin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Thrombin
  • 4.6.1. Thrombin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Cellulose
  • 4.7.1. Cellulose Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Collagen
  • 4.8.1. Collagen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Gelatin
  • 4.9.1. Gelatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Adhesives
  • 4.10.1. Adhesives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Topical Hemostat Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Topical Hemostat Market: Application Movement Analysis
• 5.3. Topical Hemostat Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. General Surgery
  • 5.5.1. General Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Neurosurgery
  • 5.6.1. Neurosurgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Vascular Surgery
  • 5.7.1. Vascular Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Cardiovascular Surgery
  • 5.8.1. Cardiovascular Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Topical Hemostat Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Topical Hemostat Market: End-use Movement Analysis
• 6.3. Topical Hemostat Market by Ens-use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Ambulatory Surgical Centers
  • 6.6.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Topical Hemostat Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Topical Hemostat Market movement analysis
• 7.3. Topical Hemostat Market: Regional Estimates & Trend Analysis by Technology & Usability
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. BD
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Type benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Medicom
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Type benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Baxter
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Type benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. HemoSonics
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Type benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Hemostasis, LLC
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Type benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Medline Industries
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Type benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Pfizer Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Type benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Johnson & Johnson
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Type benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. HemCon Medical Technologies Inc.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Type benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Integra LifeSciences
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Type benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Teleflex Incorporated
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Type benchmarking
    • 8.2.11.4. Strategic initiatives

관련자료